We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Karthik
Ramasamy
karthik.ramasamy@ouh.nhs.uk
Mr
Richard
Brouwer
richard.brouwer@ouh.nhs.uk
Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissueNeoplasms of uncertain or unknown behaviour
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Monoclonal gammopathy of undetermined significance (MGUS) is the distinct precursor to Multiple Myeloma (MM), a rare blood cancer affecting over 5000 people a year in the UK. Although Myeloma is the only clinical state offered therapy, a small number of MGUS patients suffer complications and these are referred to having monoclonal gammopathy of clinical significance (MGCS). Early detection is a high priority for Myeloma patients and drastically improves survival but has the longest diagnostic delay of any cancer. Most avoidable delays occur in primary care for reasons including inconsistent MGUS testing and follow-up. Because MGUS precedes all myelomas, an early diagnosis strategy is to regularly monitor people with MGUS for progression to myeloma. Progression risk, although difficult to define is ~1%/year with a general MGUS population prevalence of 3.2% in individuals > 50 years. Unfortunately, MGUS is often diagnosed incidentally and 80–90% of myelomas are diagnosed without first receiving an MGUS diagnosis.
SECURE is a prospective long-term observational study, which will help confirm the rate at which patients with MGUS progress to a diagnosis of MM. We hope to further our understanding of screening, diagnosis, and monitoring patterns of patients with MGUS and MGCS in the UK. We also aim to improve the understanding of demographic associations and family linkage of those with MGUS. Currently there is limited information available to understand the psychological needs after diagnosis and during the progression of the disease, so the study will additionally focus on this along with the quality of life of participants.
Participants will be required to answer surveys and questionnaires annually for a period of 5 years or until disease progression across 20 NHS sites and will be asked to provide blood samples for biomarker and metabolomic analysis. Funding is initially provided by CRUK Cancer Centre Oxford and the Medical Research Council.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
• Those who are unable or unwilling to give informed consent • Patients under the age of 18 • Patients with no evidence of MGUS • Patients with a light chain ratio of 0.3 to 3.0 without a monoclonal protein on serum electrophoresis or immunofixation • Patients with rapidly rising paraprotein or serum free light chains of progressive disease at time of diagnosis or inclusion into study
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST and funded by Medical Research Council (MRC) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 54152
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
